Outcomes with brachytherapy based dose escalation for gleason 8 versus 9-10 prostate cancer: An NCDB analysis

CONCLUSION: BT was associated with improved OS when compared to 7560 - 8640 cGy in GS 8, but not in Gleason 9-10 disease. This hypothesis generating study suggests there may be variable benefit with BT in high risk prostate cancer patients on OS. Future prospective studies are needed to investigate whether the benefit of BT is similar across all high risk prostate cancer patients.PMID:34049784 | DOI:10.1016/j.urolonc.2021.04.014

Source: Urologic Oncology - May 29, 2021 Category: Urology & Nephrology Authors: John David Michael Luu Diana Lu Zachary S Zumsteg Howard Sandler Mitchell Kamrava Source Type: research